Peter Swetly
Corporate Officer/Principal chez University of Vienna
Profil
Peter Swetly is the founder of ORIDIS Biomed Forschungs & Entwicklungs GmbH, which was founded in 2001.
He currently holds the position of Vice Chancellor at the University of Vienna.
Previously, he worked as a Director-Research & Development at Boehringer Ingelheim GmbH.
Postes actifs de Peter Swetly
| Sociétés | Poste | Début |
|---|---|---|
| University of Vienna | Corporate Officer/Principal | 20/01/2010 |
Anciens postes connus de Peter Swetly
| Sociétés | Poste | Fin |
|---|---|---|
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Directeur Technique/Scientifique/R&D | - |
ORIDIS Biomed Forschungs & Entwicklungs GmbH
 ORIDIS Biomed Forschungs & Entwicklungs GmbH Medical SpecialtiesHealth Technology ORIDIS Biomed - a specialist in tissue-based cancer research - is a Contract Research Organization founded in 2001 as a spin-off from the Medical University of Graz. Based on its unique clinical and biobank network and its sound molecular pathological expertise ORIDIS Biomed designs and performs retrospective and prospective customized tissue- and body fluid- based studies. The company brings value to its customers by evaluation of the medical and clinical relevance of drug targets, mode-of-action models and biomarker candidates for patient stratification and diagnosis. ORIDIS Biomed's unique offering combines its proprietary TISSOMIC research platform and proven experience in analysis of clinically relevant tissue with access to a biobank with 2.9 million samples of diseased human tissue and associated data. Research activities at ORIDIS Biomed are focused on the validation and development of tissue- and blood-based nucleic acid biomarkers for early cancer diagnosis, patient stratification and therapy monitoring. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
ORIDIS Biomed Forschungs & Entwicklungs GmbH
ORIDIS Biomed Forschungs & Entwicklungs GmbH Medical SpecialtiesHealth Technology ORIDIS Biomed - a specialist in tissue-based cancer research - is a Contract Research Organization founded in 2001 as a spin-off from the Medical University of Graz. Based on its unique clinical and biobank network and its sound molecular pathological expertise ORIDIS Biomed designs and performs retrospective and prospective customized tissue- and body fluid- based studies. The company brings value to its customers by evaluation of the medical and clinical relevance of drug targets, mode-of-action models and biomarker candidates for patient stratification and diagnosis. ORIDIS Biomed's unique offering combines its proprietary TISSOMIC research platform and proven experience in analysis of clinically relevant tissue with access to a biobank with 2.9 million samples of diseased human tissue and associated data. Research activities at ORIDIS Biomed are focused on the validation and development of tissue- and blood-based nucleic acid biomarkers for early cancer diagnosis, patient stratification and therapy monitoring. | Health Technology |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |